SCHEMBL1751891

SCHEMBL1751891

O=c1ccc(-c2ccncc2)n[nH]1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.68
LMNA P02545 3/20 0.63
KMT2A Q03164 2/20 0.63
MEN1 O00255 1/20 0.63
PDE3B Q13370 5/20 0.57
PDE3A Q14432 5/20 0.57
MAPT P10636 1/20 0.50
PDE4A P27815 3/20 0.49
PDE4B Q07343 3/20 0.49
PDE4C Q08493 3/20 0.49
PDE4D Q08499 3/20 0.49
GSK3B P49841 3/20 0.44
IDO1 P14902 1/20 0.44
HRH3 Q9Y5N1 4/20 0.42
TP53 P04637 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL11239163 0.98 CYP1A2 (0.66) CYP1A2LMNAKMT2AMEN1PDE3B
SCHEMBL3452908 0.87 LMNA (0.80) CYP1A2LMNAKMT2AMEN1PDE3B
SCHEMBL7270728 0.84 LMNA (0.56) CYP1A2LMNAKMT2AMEN1PDE3B
Hydrochloric Acid SCHEMBL10741298 0.83 LMNA (0.54) CYP1A2LMNAKMT2AMEN1PDE3B
SCHEMBL482059 0.81 CYP1A2 (1.00) CYP1A2LMNAKMT2AMEN1PDE3B
SCHEMBL1456606 0.79 CYP1A2 (0.67) CYP1A2LMNAKMT2AMEN1PDE3B
SCHEMBL9687063 0.79 LMNA (0.69) CYP1A2LMNAKMT2AMEN1PDE3B
SCHEMBL7689907 0.79 CYP1A2 (0.96) CYP1A2LMNAKMT2AMEN1PDE3B
SCHEMBL11156334 0.79 CYP1A2 (0.67) CYP1A2LMNAKMT2AMEN1PDE3B
SCHEMBL4122238 0.78 LMNA (0.67) CYP1A2LMNAKMT2AMEN1PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119855813-A Pyridazinone-derived compounds for modulating MYC and for medical use 遗传智力公司 2025-04-18 CN claimed
US-4304777-A 6-(Pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics STERLING DRUG INC. (US) 1981-12-08 US claimed
US-20250368623-A1 PYRIDAZINONE-DERIVED COMPOUNDS FOR THE MODULATION OF MYC AND FOR MEDICAL USES GENETIC INTELLIGENCE INC (US) 2025-12-04 US disclosed
CN-119855813-A Pyridazinone-derived compounds for modulating MYC and for medical use 遗传智力公司 2025-04-18 CN disclosed
CN-115872976-B Quinoline derivative, pharmaceutical composition containing quinoline derivative and application of pharmaceutical composition 中国药科大学 2024-05-14 CN disclosed
CN-115872976-A Quinoline derivative, pharmaceutical composition containing quinoline derivative and application of quinoline derivative 中国药科大学 2023-03-31 CN disclosed
EP-2655357-B1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO SA (CH) 2016-06-22 EP disclosed
CN-103429585-B Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors MERCK SERONO SA 2015-07-08 CN disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 US disclosed
EP-1753743-B1 PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS DEUTSCHLAND (DE) 2015-03-04 EP disclosed
CN-103429585-A Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors MERCK SERONO SA 2013-12-04 CN disclosed
EP-1598348-A1 Novel pyridazinone derivatives as inhibitors of CDK2 Aventis Pharma Deutschland GmbH (DE) 2005-11-23 EP disclosed
US-4590194-A 3-[methyl or dimethyl)amino]-6-(pyridinyl)pyridazines and their cardiotonic use STERLING DRUG INC. (US) 1986-05-20 US disclosed
US-4486431-A Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones STERLING DRUG INC. (US) 1984-12-04 US disclosed
US-4346221-A Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones STERLING DRUG INC. (US) 1982-08-24 US disclosed
US-4338446-A Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates STERLING DRUG INC. (US) 1982-07-06 US disclosed
US-4337253-A 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic STERLING DRUG INC. (US) 1982-06-29 US disclosed
US-4305943-A 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics STERLING DRUG INC. (US) 1981-12-15 US disclosed
US-4304776-A 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics STERLING DRUG INC. (US) 1981-12-08 US disclosed
US-4304777-A 6-(Pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics STERLING DRUG INC. (US) 1981-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368623-A1 PYRIDAZINONE-DERIVED COMPOUNDS FOR THE MODULATION OF MYC AND FOR MEDICAL USES MYC, MYCBP, MKI67 CYP1A2 702/4885LMNA 1051/4885KMT2A 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.